Determination of tamoxifen and its metabolites in human plasma by nonaqueous capillary electrophoresis with contactless conductivity detection

A new approach for the quantification of tamoxifen and its metabolites 4‐hydroxytamoxifen, N‐desmethyltamoxifen, and 4‐hydroxy‐N‐desmethyltamoxifen (endoxifen) in human plasma samples using NACE coupled with contactless conductivity detection (C⁴D) is presented. The buffer system employed consisted...

Full description

Saved in:
Bibliographic Details
Published in:Electrophoresis 2015-11, Vol.36 (21-22), p.2713-2719
Main Authors: Thang, Lee Yien, Shahir, Shafinaz, See, Hong Heng
Format: Article
Language:English
Subjects:
acetic acid
Breast
Breast cancer
breast neoplasms
capillary electrophoresis
Contactless conductivity detection
correlation
deoxycholic acid
Electrophoresis
Human
humans
Linearity
Metabolites
methanol
Methyl alcohol
Nonaqueous capillary electrophoresis
Patients
Plasma
sodium
Tamoxifen
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A new approach for the quantification of tamoxifen and its metabolites 4‐hydroxytamoxifen, N‐desmethyltamoxifen, and 4‐hydroxy‐N‐desmethyltamoxifen (endoxifen) in human plasma samples using NACE coupled with contactless conductivity detection (C⁴D) is presented. The buffer system employed consisted of 7.5 mM deoxycholic acid sodium salt, 15 mM acetic acid, and 1 mM 18‐crown‐6 in 100% methanol. The complete separation of all targeted compounds (including endoxifen racemate) could be achieved within 6 min under optimized conditions. The proposed method was validated and showed good linearity in the range from 100 to 5000 ng/mL with correlation coefficients between 0.9922 and 0.9973, LODs in the range of 25–40 ng/mL, and acceptable reproducibility of the peak area (intraday RSD 2.2–3.1%, n = 4; interday (3 days) RSD 6.0–8.8%, n = 4). The developed method was successfully demonstrated for the quantification of tamoxifen and its metabolites in human plasma samples collected from breast cancer patients undertaking tamoxifen treatment.
ISSN:0173-0835
1522-2683
DOI:10.1002/elps.201500164